# US 8,772,261 B2 · Treatment of tumors with genetically engineered herpes virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,772,261 B2
- Document ID: US8772261B2
- Status: Granted
- Kind: B2
- Application number: 13/656,195
- Filed: 2012-10-19
- Published: 2013-02-14
- Granted: 2014-07-08
- Earliest claimed: 2000-07-31
- Assignees: Arch Development Corporation
- Applicants: Arch Development Corporation; UAB Research Foundation
- Inventors: Ralph R. Weichselbaum; Bernard Roizman; Richard J. Whitley
- Web page: https://patentgrep.com/patent/US8772261B2

## CPC

- C07K 14/005: from viruses
- A61K 35/763: Herpes virus
- A61P 35/00: Antineoplastic agents
- C12N 2710/16622: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/16632: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed are methods for treating cancer by administering an effective amount of a modified Herpes simplex virus.

## Claims

### Claim 1

A method for reducing a non-central nervous system tumor mass comprising the step of administering to an individual suffering from cancer an amount of a Herpes simplex virus (HSV) comprising a modified HSV genome wherein said modification comprises a deletion of a gene dispensable for viral replication in culture and a modification of an inverted repeat region of said HSV genome such that one γ134.5 gene remains intact, said amount of HSV being effective to reduce the non-central nervous system tumor mass and safe for administration to the patient.

### Claim 2 (depends on 1)

The method of claim 1 wherein the modification of the inverted repeat region of the genome comprises an alteration of a copy of a γ134.5 gene which renders that copy of the gene incapable of expressing an active gene product.

### Claim 3 (depends on 2)

The method of claim 2 wherein the alteration of the γ134.5 gene comprises an insertion of a DNA sequence comprising one or more nucleotides into the coding region or regulatory region of the gene.

### Claim 4 (depends on 2)

The method of claim 2 wherein the alteration of the γ134.5 gene comprises a deletion of all or part of the coding region or regulatory region of the gene.

### Claim 5 (depends on 1)

The method of claim 1 wherein the modified HSV genome further comprises an alteration in a unique region of the HSV genome.

### Claim 6 (depends on 1)

The method of claim 1 wherein the modified HSV genome further comprises a cytokine.